selective, reversible LSD1 inhibitor
<100 mg orally QW, in Ph. II for 1L ES-SCLC
from 300k+ cmpd HTS, SBDD + opt.
J. Med. Chem., Oct. 9, 2020
Celgene/Bristol Myers Squibb, San Diego, CA
CC-90011
1 min read
CC-90011 (Celgene/Bristol Myers Squibb (BMS)) selective, reversible LSD1 inhibitor clinical candidate)
Search By Structure
- BAY 1214784
- BAY 1217224
- CC-90011
- LEO 39652
- OATD-01
- AG-636
- “compound 46”
- “compound 25”
- “lipid 10a”
- BAY-6672
- “compound 27”
- “EST73502”
- CG428
- “compound 34”
Molecules of the Month
2023
2022
2021
2020